Report an error

Spotted something inaccurate in “SGLT2 Inhibitors' Cardio-Renal Benefits Weighed Against Rare Ketoacidosis Risk”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.